https://www.selleckchem.com/pr....oducts/vevorisertib-
3 Gy. Compared with the placebo arm, the low-dose tamoxifen arm participants had significantly lower mammographic dense area ( = 0.02) and IGF1 levels ( 0.0001), and higher IGFBP-3 levels ( = 0.02). There was no difference in toxicity biomarkers (serum bone-specific alkaline phosphatase, lipids, and antithrombin III; urine N-telopeptide cross-links) between the treatment arms. We did not identify any grade 3-4 adverse events related to low-dose tamoxifen. In this randomized trial in chest-irradiated cancer sur
Like
Comment
Share
